/LENZ

LENZ Therapeutics Inc

LENZ

$4.52USD↓-4.24%-0.20 today

MARKET CAP

142.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$5

$50

AI Summary

Stalk

TrimMedium

LENZ is in a Stage 4 decline with persistent lower highs and lower lows under down-sloping EMAs, confirming bearish structure across both medium and long terms. Short-term execution timing is neutral as price tightly tracks below declining EMAs amid extreme oversold readings, offering no clear entry. With a speculative strategy requiring high selectivity, execution is deferred and best considered on any rally into EMA resistance.

↑Moderate Buy consensus with $28.80 price target implies ~509% upside.
↑VIZZ prescriptions surged 45% month-over-month after marketing push.
↓Q2 2026 net loss of $31.9M despite VIZZ revenue growth.

Full analysis →

Buying

8

institutions

Selling

1

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.29 M	13.02 M	+315.30 K	-28.0%	0.00%
MM Millennium Management LLC Q2 2026	BUY	1.51 M	8.57 M	+639.22 K	+7.7%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	580.63 K	3.30 M	+426.93 K	+134.5%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	227.73 K	1.29 M	+87.43 K	+0.8%	0.00%
WP Woodline Partners LP Q2 2026	SELL	100.00 K	568.00 K	+-100.00 K	-69.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	BUY	92.35 K	524.55 K	+19.01 K	-21.8%	0.00%
RT Renaissance Technologies LLC Q2 2026	BUYNEW	70.63 K	401.17 K	+70.63 K	+0.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUY	18.20 K	103.36 K	+4.63 K	-16.8%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	11.98 K	69.01 K	+1.10 K	-23.5%	0.00%